Stan Abel Net Worth

Stan Abel biography

Stan E. Abel CPA serves as Director of the Company. Stan E. Abel joined the Adynxx board in 2008, bringing to the company more than 20 years of operational, development and financial management experience. Stan is the President and Chief Executive Officer of SiteOne Therapeutics, a pain company focused on developing a novel platform of highly selective sodium channel 1.7 inhibitors. Stan previously served as Chief Executive Officer of Corthera, Inc., from October 2007 through the successful sale of the company to Novartis in February 2010. Prior to joining Corthera, Stan served as the Chief Financial Officer of Cerexa, Inc. from its inception in July 2005 through the successful sale of the company to Forest Laboratories in January 2007. Prior to Cerexa‚ Stan was the Chief Financial Officer of Peninsula Pharmaceuticals, Inc. from January 2003 through the sale of the company to Johnson & Johnson in June 2005. Stan was responsible for all financial activities of the company, raising over $70M in private financing and leading the company through the initial public offering process. Stan also played a key role in structuring the spin-out of Cerexa and the acquisition of Peninsula by Johnson & Johnson. Earlier in his career‚ Stan spent four years at Eli Lilly and Company within the finance and strategy organizations. He also held a variety of financial leadership positions during his nine years at DowBrands‚ Inc., a wholly-owned subsidiary of The Dow Chemical Company. Stan received a B.S. in business from Indiana University and an M.B.A.‚ with honors‚ from the University of Chicago. He received his CPA from the state of Indiana in 1995.

What's Stan Abel's mailing address?

Stan's mailing address filed with the SEC is C/O ADYNXX, INC., 100 PINE ST., STE. 500, SAN FRANCISCO, CA, 94111.

What does Adynxx do?

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Adynxx executives and stock owners

Adynxx executives and other stock owners filed with the SEC include:

• Richard Orr,
  Pres, CEO, Principal Financial Officer & Director
• Dr. Julien Mamet Ph.D.,
  Founder, Chief Scientific Officer & Director
• Eckard Weber,
  Director
• Matthew Ruth,
  Director
• Gregory Flesher,
  Director
• Stan Abel,
  Director
• Donald Manning,
  Chief Medical Officer
• Julien Mamet,
  Chief Scientific Officer, Director
• Rick Orr,
  Chief Executive Officer, Principal Financial Officer, Director
• Dennis Podlesak,
  Chairman of the Board
• Kimberley Hebert,
  Sr. Director of Clinical Operations
• Dina Gonzalez,
  Principal Accounting Officer & Sr. VP of Fin.
• William Martin,
  Exec. VP of Corp. Devel. & Operations